Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bas J M Peters

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Lung Cancer (Amsterdam, Netherlands)|December 11, 2025
Reply to letter to the editor "The effectiveness of pembrolizumab maintenance with or without pemetrexed after induction treatment for advanced non-squamous Non-Small-Cell lung cancer"Bas J M Peters, Stefan Böhringer, Esmee van Geffen
Current Opinion in Pulmonary Medicine|March 14, 2019
Treatment of oncogene-driven non-small cell lung cancerElisabeth A Kastelijn, Adrianus J de Langen, Bas J M Peters
Chemotherapy|December 21, 2018
Recurrent Episodes of Nivolumab-Induced Pneumonitis after Nivolumab Discontinuation and the Time Course of Carcinoembryonic Antigen Levels: A Case of a 58-Year-Old Woman with Non-Small Cell Lung CancerCorine de Jong, Bas J M Peters, Franz M N H Schramel
Cells|March 6, 2021
Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis PatientsBas J M Peters, Anish Bhatoe, Adriane D M Vorselaars, et al.
Mabs|December 21, 2012
Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin (bevacizumab), Remicade (infliximab) and Herceptin (trastuzumab)Bas J M Peters, Martinus A H Capelle, Tudor Arvinte, et al.
The Journal of Pharmacy and Pharmacology|May 22, 2010
Methodological and statistical issues in pharmacogenomicsBas J M Peters, Andrei S Rodin, Anthonius de Boer, et al.
Expert Review of Cardiovascular Therapy|August 14, 2009
Genetic determinants of response to statinsBas J M Peters, Olaf H Klungel, Anthonius de Boer, et al.
Anticancer Research|January 31, 2021
Evaluation of Serum Biomarker CEA and Ca-125 as Immunotherapy Response Predictors in Metastatic Non-small Cell Lung CancerMax R Clevers, Elisabeth A Kastelijn, Bas J M Peters, et al.
Cancer Epidemiology|July 25, 2016
Quantitative and qualitative assessment of real world data comparative effectiveness research of systemic therapies in lung oncology: A systematic reviewBas J M Peters, Vivi E M T Janssen, Franz M Schramel, et al.
Clinical Cases in Mineral and Bone Metabolism : the Official Journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases|March 31, 2012
Pharmacogenetics of cardiovascular drug therapyBas J M Peters, Olaf H Klungel, Anthonius de Boer, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Lung Cancer (Amsterdam, Netherlands)|December 11, 2025
Reply to letter to the editor "The effectiveness of pembrolizumab maintenance with or without pemetrexed after induction treatment for advanced non-squamous Non-Small-Cell lung cancer"Bas J M Peters, Stefan Böhringer, Esmee van Geffen
Current Opinion in Pulmonary Medicine|March 14, 2019
Treatment of oncogene-driven non-small cell lung cancerElisabeth A Kastelijn, Adrianus J de Langen, Bas J M Peters
Chemotherapy|December 21, 2018
Recurrent Episodes of Nivolumab-Induced Pneumonitis after Nivolumab Discontinuation and the Time Course of Carcinoembryonic Antigen Levels: A Case of a 58-Year-Old Woman with Non-Small Cell Lung CancerCorine de Jong, Bas J M Peters, Franz M N H Schramel
Cells|March 6, 2021
Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis PatientsBas J M Peters, Anish Bhatoe, Adriane D M Vorselaars, et al.
Mabs|December 21, 2012
Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin (bevacizumab), Remicade (infliximab) and Herceptin (trastuzumab)Bas J M Peters, Martinus A H Capelle, Tudor Arvinte, et al.
The Journal of Pharmacy and Pharmacology|May 22, 2010
Methodological and statistical issues in pharmacogenomicsBas J M Peters, Andrei S Rodin, Anthonius de Boer, et al.
Expert Review of Cardiovascular Therapy|August 14, 2009
Genetic determinants of response to statinsBas J M Peters, Olaf H Klungel, Anthonius de Boer, et al.
Anticancer Research|January 31, 2021
Evaluation of Serum Biomarker CEA and Ca-125 as Immunotherapy Response Predictors in Metastatic Non-small Cell Lung CancerMax R Clevers, Elisabeth A Kastelijn, Bas J M Peters, et al.
Cancer Epidemiology|July 25, 2016
Quantitative and qualitative assessment of real world data comparative effectiveness research of systemic therapies in lung oncology: A systematic reviewBas J M Peters, Vivi E M T Janssen, Franz M Schramel, et al.
Clinical Cases in Mineral and Bone Metabolism : the Official Journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases|March 31, 2012
Pharmacogenetics of cardiovascular drug therapyBas J M Peters, Olaf H Klungel, Anthonius de Boer, et al.
Pageof 4